Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 8/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.55 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.55 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.55 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.55 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.55 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213874 | 1.00 | G6PD (0.71) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6830022 | 1.00 | G6PD (0.71) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3669161 | 1.00 | G6PD (0.71) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19156397 | 1.00 | G6PD (0.71) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11103160 | 1.00 | G6PD (0.71) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27876896 | 0.90 | G6PD (0.57) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3988193 | 0.88 | G6PD (0.58) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3122440 | 0.88 | G6PD (0.72) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL11350178 | 0.88 | G6PD (0.72) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL9623226 | 0.88 | G6PD (0.56) | G6PDKMT2ACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226349-A1 | TOPICAL NEUROSTEROID FORMULATIONS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-07-21 | — | — | US | claimed |
| EP-4017498-A1 | TOPICAL NEUROSTEROID FORMULATIONS | Arizona Board of Regents on behalf of the University of Arizona (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021034883-A1 | TOPICAL NEUROSTEROID FORMULATIONS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-02-25 | — | — | WO | claimed |
| EP-3773599-A1 | GABA-A ANTAGONISTS FOR TREATING SUBSTANCE WITHDRAWAL DISORDERS | Asarina Pharma ApS (DK) | 2021-02-17 | — | — | EP | claimed |
| WO-2019193138-A1 | GABA-A ANTAGONISTS FOR TREATING SUBSTANCE WITHDRAWAL DISORDERS | ASARINA PHARMA APS (DK) | 2019-10-10 | — | — | WO | claimed |
| WO-2018147791-A1 | 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE FOR USE IN TREATMENT OF ESSENTIAL TREMOR | ASARINA PHARMA AB (SE) | 2018-08-16 | — | — | WO | claimed |
| WO-2014107794-A1 | FORMULATIONS AND METHODS FOR THEIR USE IN TREATMENT OF NEUROPATHOLOGY AND NEURODEGENERATION AS A RESULT OF TRAUMATIC INJURY | SAPNA LIFE SCIENCES CORP. (CA) | 2014-07-17 | — | — | WO | claimed |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | PURETECH LYT, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20240117436-A1 | METHODS OF TREATING LIPEDEMA INCLUDING AKR1C2 AS A THERAPEUTIC TARGET | MAGI EUREGIO SCS (IT) | 2024-04-11 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4100017-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PureTech LYT, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-115348864-A | Lipid prodrugs of neurosteroids | 纯技术LYT股份有限公司 | 2022-11-15 | — | — | CN | disclosed |
| WO-2008066899-A2 | NANOPARTICULATE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF | MARINUS PHARMACEUTICALS (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-1812009-A1 | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | Umecrine AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006054938-A1 | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2006-05-26 | — | — | WO | disclosed |
| EP-1458399-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | Umecrine AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003059357-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2003-07-24 | — | — | WO | disclosed |
| EP-0554436-A4 | — | — | 1994-01-12 | — | — | EP | disclosed |
| EP-0554436-A1 | GABA RECEPTOR MODULATORS | COCENSYS, INC. (US) | 1993-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | G6PD 1035/4885KMT2A 3097/4885CYP1A2 83/4885 |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | G6PD 1035/4885KMT2A 3097/4885CYP1A2 83/4885 |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | CYP21A2, CYP46A1, CYP17A1 | G6PD 1035/4885KMT2A 3097/4885CYP1A2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.